Rajnish Mehrotra

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8537511/publications.pdf

Version: 2024-02-01

235 papers 14,158 citations

63 h-index 24258 110 g-index

239 all docs 239 docs citations

times ranked

239

10843 citing authors

#	Article	IF	CITATIONS
1	Comparative Effectiveness of Dialysis Modality on Laboratory Parameters of Mineral Metabolism. American Journal of Nephrology, 2022, 53, 157-168.	3.1	2
2	ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Peritoneal Dialysis International, 2022, 42, 110-153.	2.3	209
3	Comparison of mortality between Medicare Advantage and traditional Medicare beneficiaries with kidney failure. American Journal of Managed Care, 2022, 28, 180-186.	1.1	1
4	Impact of Removing Race Variable on CKD Classification Using the Creatinine-Based 2021 CKD-EPI Equation. Kidney Medicine, 2022, 4, 100471.	2.0	5
5	Establishing a core outcome measure for life participation in patients receiving peritoneal dialysis: A Standardised Outcomes in Nephrology–Peritoneal Dialysis consensus workshop report. Peritoneal Dialysis International, 2022, 42, 562-570.	2.3	7
6	Treating Home Versus Predialysis Blood Pressure Among In-Center Hemodialysis Patients: A Pilot Randomized Trial. American Journal of Kidney Diseases, 2021, 77, 12-22.	1.9	9
7	The Microbiome and p-Inulin in Hemodialysis: A Feasibility Study. Kidney360, 2021, 2, 445-455.	2.1	3
8	KDOQI US Commentary on the 2020 ISPD Practice Recommendations for Prescribing High-Quality Goal-Directed Peritoneal Dialysis. American Journal of Kidney Diseases, 2021, 77, 157-171.	1.9	22
9	ISPD recommendations for the evaluation of peritoneal membrane dysfunction in adults: Classification, measurement, interpretation and rationale for intervention. Peritoneal Dialysis International, 2021, 41, 352-372.	2.3	42
10	Development and Content Validity of a Patient-Reported Experience Measure for Home Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 588-598.	4.5	20
11	Medicaid Expansion and Incidence of Kidney Failure among Nonelderly Adults. Journal of the American Society of Nephrology: JASN, 2021, 32, 1425-1435.	6.1	9
12	MO680INTERNATIONAL COMPARISONS OF ICODEXTRIN PRESCRIPTION PRACTICE AND ITS ASSOCIATION WITH FLUID REMOVAL, BLOOD PRESSURE, PATIENT AND TECHNIQUE SURVIVAL*. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
13	Ambulatory and Home Blood Pressure Monitoring in Hemodialysis Patients: A Mixed-Methods Study Evaluating Comparability and Tolerability of Blood Pressure Monitoring. Kidney Medicine, 2021, 3, 457-460.	2.0	3
14	A genome-wide association study suggests correlations of common genetic variants with peritoneal solute transfer rates in patients with kidney failure receiving peritoneal dialysis. Kidney International, 2021, 100, 1101-1111.	5.2	13
15	Calculating estimated glomerular filtration rate without the race correction factor: Observations at a large academic medical system. Clinica Chimica Acta, 2021, 520, 16-22.	1.1	15
16	Patient Activation Measure in Dialysis Dependent Patients in the United States. Journal of the American Society of Nephrology: JASN, 2021, , ASN.2021030315.	6.1	5
17	The challenge of insomnia for patients on haemodialysis. Nature Reviews Nephrology, 2021, 17, 147-148.	9.6	15
18	Evaluation of Racial, Ethnic, and Socioeconomic Disparities in Initiation of Kidney Failure Treatment During the First 4 Months of the COVID-19 Pandemic. JAMA Network Open, 2021, 4, e2127369.	5.9	14

#	Article	IF	CITATIONS
19	Scope and heterogeneity of outcomes reported in randomized trials in patients receiving peritoneal dialysis. CKJ: Clinical Kidney Journal, 2021, 14, 1817-1825.	2.9	4
20	Patient-reported outcome measures for life participation in peritoneal dialysis: a systematic review. Nephrology Dialysis Transplantation, 2021, 36, 890-901.	0.7	9
21	Despite National Declines In Kidney Failure Incidence, Disparities Widened Between Low- And High-Poverty US Counties. Health Affairs, 2021, 40, 1900-1908.	5 . 2	6
22	Trends in Mortality Among Patients Initiating Maintenance Dialysis in Puerto Rico Compared to US States, 2006-2015. American Journal of Kidney Diseases, 2020, 75, 296-298.	1.9	2
23	Advancing American Kidney Healthâ€"New Opportunities for Collaborative Care. American Journal of Medicine, 2020, 133, e335-e337.	1.5	6
24	The current and future landscape of dialysis. Nature Reviews Nephrology, 2020, 16, 573-585.	9.6	252
25	Meaning of empowerment in peritoneal dialysis: focus groups with patients and caregivers. Nephrology Dialysis Transplantation, 2020, 35, 1949-1958.	0.7	46
26	Combination Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD (HIDE): A Randomized, Placebo-Controlled, Pilot Trial. Kidney360, 2020, 1, 1380-1389.	2.1	2
27	Sleep-HD trial: short and long-term effectiveness of existing insomnia therapies for patients undergoing hemodialysis. BMC Nephrology, 2020, 21, 443.	1.8	10
28	Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney International, 2020, 97, 1117-1129.	5.2	407
29	"Can I go to Glasgow?―Learnings from patient involvement at the 17th Congress of the International Society for Peritoneal Dialysis (ISPD). Peritoneal Dialysis International, 2020, 40, 12-25.	2.3	5
30	Establishing a Core Outcome Set for Peritoneal Dialysis: Report of the SONG-PD (Standardized) Tj ETQq0 0 0 rgBT Diseases, 2020, 75, 404-412.	T /Overlock 1.9	k 10 Tf 50 30 92
31	Counterpoint: Twice-Weekly Hemodialysis Should Be an Approach of Last Resort Even in Times of Dialysis Unit Stress. Journal of the American Society of Nephrology: JASN, 2020, 31, 1143-1144.	6.1	15
32	Attitudes toward Peritoneal Dialysis among Peritoneal Dialysis and Hemodialysis Medical Directors. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1067-1070.	4.5	9
33	CJASN and Disclosure of Conflicts of Interest. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 785-786.	4.5	1
34	Peritoneal Dialysis Access Associated Infections. Advances in Chronic Kidney Disease, 2019, 26, 23-29.	1.4	22
35	Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 96, 37-47.	5.2	235
36	An international Delphi survey helped develop consensus-based core outcome domains for trialsÂin peritoneal dialysis. Kidney International, 2019, 96, 699-710.	5.2	73

#	Article	IF	Citations
37	Comparative Efficacy of Therapies for Treatment of Depression for Patients Undergoing Maintenance Hemodialysis. Annals of Internal Medicine, 2019, 170, 369.	3.9	73
38	Advancing American Kidney Health. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1788-1788.	4.5	42
39	Patient and Caregiver Priorities for Outcomes in Peritoneal Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 74-83.	4.5	101
40	Fostering Innovation in Symptom Management among Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 150-160.	4.5	60
41	Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial. Kidney International, 2019, 95, 973-982.	5.2	70
42	Numbers or symptoms: when to initiate dialysis?. Nephrology Dialysis Transplantation, 2018, 33, 904-905.	0.7	2
43	CJASN: What's Behind and What's Ahead. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 3-3.	4.5	2
44	Impact of Obesity on Modality Longevity, Residual Kidney Function, Peritonitis, and Survival Among Incident Peritoneal Dialysis Patients. American Journal of Kidney Diseases, 2018, 71, 802-813.	1.9	46
45	Weekly Standard Kt/Vurea and Clinical Outcomes in Home and In-Center Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 445-455.	4.5	16
46	Peritoneal dialysis education: Challenges and innovation. Seminars in Dialysis, 2018, 31, 107-110.	1.3	13
47	Symptom Prioritization among Adults Receiving In-Center Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 735-745.	4.5	100
48	Association of Medicaid Expansion With 1-Year Mortality Among Patients With End-Stage Renal Disease. JAMA - Journal of the American Medical Association, 2018, 320, 2242.	7.4	78
49	Predictors of early mortality and readmissions among dialysis patients undergoing lower extremity amputation. Journal of Vascular Surgery, 2018, 68, 1505-1516.	1.1	20
50	FP495PATIENT AND CAREGIVER PRIORITIES FOR OUTCOMES IN PERITONEAL DIALYSIS: AN INTERNATIONAL NOMINAL GROUP STUDY. Nephrology Dialysis Transplantation, 2018, 33, i205-i205.	0.7	0
51	Young Kidney Professionals' Perspectives and Attitudes about Consuming Scientific Information. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1587-1597.	4.5	1
52	Urine Complement Proteins and the Risk of Kidney Disease Progression and Mortality in Type 2 Diabetes. Diabetes Care, 2018, 41, 2361-2369.	8.6	21
53	Effect of high-protein meals during hemodialysis combined with lanthanum carbonate in hypoalbuminemic dialysis patients: findings from the FrEDI randomized controlled trial. Nephrology Dialysis Transplantation, 2017, 32, gfw323.	0.7	24
54	CJASN: Turning the Page. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1-2.	4.5	2

#	Article	IF	Citations
55	Introduction to 30ÂYears: Lessons Learned in Dialysis. Seminars in Dialysis, 2017, 30, 85-85.	1.3	o
56	Initial Session Duration and Mortality Among IncidentÂHemodialysis Patients. American Journal of Kidney Diseases, 2017, 70, 69-75.	1.9	9
57	Components of A Successful Peritoneal Dialysis Program. Seminars in Nephrology, 2017, 37, 10-16.	1.6	10
58	Sex Differences in Hospitalizations with Maintenance Hemodialysis. Journal of the American Society of Nephrology: JASN, 2017, 28, 2721-2728.	6.1	47
59	Timing of Dialysis Initiation: What Has Changed Since IDEAL?. Seminars in Nephrology, 2017, 37, 181-193.	1.6	35
60	Predictive Score for Posttransplantation Outcomes. Transplantation, 2017, 101, 1353-1364.	1.0	39
61	Changes in the worldwide epidemiology of peritoneal dialysis. Nature Reviews Nephrology, 2017, 13, 90-103.	9.6	384
62	Vascular Access for Hemodialysis and Value-Based Purchasing for ESRD. Journal of the American Society of Nephrology: JASN, 2017, 28, 395-397.	6.1	9
63	Indication for Dialysis Initiation and Mortality in Patients With Chronic Kidney Failure: A Retrospective Cohort Study. American Journal of Kidney Diseases, 2017, 69, 41-50.	1.9	40
64	Perspectives on Funding Initiatives in Clinical Research in Kidney Disease in the United States. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1543-1543.	4.5	0
65	Standardized Outcomes in Nephrology—Peritoneal Dialysis (SONG-PD): Study Protocol for Establishing a Core Outcome Set in PD. Peritoneal Dialysis International, 2017, 37, 639-647.	2.3	50
66	Concurrence of Serum Creatinine and Albumin With Lower Risk for Death in Twice-Weekly Hemodialysis Patients., 2017, 27, 26-36.		18
67	Development and Validation of a Novel Laboratory-Specific Correction Equation for Total Serum Calcium and Its Association With Mortality Among Hemodialysis Patients. Journal of Bone and Mineral Research, 2017, 32, 549-559.	2.8	11
68	Racial Differences in Survival of Incident Home Hemodialysis and Kidney Transplant Patients. Transplantation, 2016, 100, 2203-2210.	1.0	5
69	Serum sodium and mortality in a national peritoneal dialysis cohort. Nephrology Dialysis Transplantation, 2016, 32, gfw254.	0.7	20
70	Patient and Other Stakeholder Engagement in Patient-Centered Outcomes Research Institute Funded Studies of Patients with Kidney Diseases. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1703-1712.	4.5	56
71	Hidden Hypercalcemia and Mortality Risk in Incident Hemodialysis Patients. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2440-2449.	3.6	26
72	Residual Kidney Function Decline and Mortality in Incident Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2016, 27, 3758-3768.	6.1	126

#	Article	IF	Citations
73	Survival of Elderly Adults Undergoing Incident Home Hemodialysis and Kidney Transplantation. Journal of the American Geriatrics Society, 2016, 64, 2003-2010.	2.6	18
74	Mean platelet volume and mortality risk in a national incident hemodialysis cohort. International Journal of Cardiology, 2016, 220, 862-870.	1.7	16
75	Examining the robustness of the obesity paradox in maintenance hemodialysis patients: a marginal structural model analysis. Nephrology Dialysis Transplantation, 2016, 31, 1310-1319.	0.7	51
76	Extended-hours hemodialysis is associated withÂlower mortality risk in patients with end-stageÂrenal disease. Kidney International, 2016, 90, 1312-1320.	5.2	32
77	Thyroid Functional Disease and Mortality in a National Peritoneal Dialysis Cohort. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4054-4061.	3.6	36
78	Serum amyloid a and risk of death and end-stage renal disease in diabetic kidney disease. Journal of Diabetes and Its Complications, 2016, 30, 1467-1472.	2.3	23
79	Treatment frequency and mortality among incident hemodialysis patients in the United States comparing incremental with standard and more frequent dialysis. Kidney International, 2016, 90, 1071-1079.	5.2	53
80	Serum Magnesium Levels and Hospitalization and Mortality in Incident Peritoneal Dialysis Patients: A Cohort Study. American Journal of Kidney Diseases, 2016, 68, 619-627.	1.9	37
81	New-Onset Diabetes in Peritoneal Dialysis Patients – Which Predictors Really Matter?. Peritoneal Dialysis International, 2016, 36, 243-246.	2.3	4
82	The Current State of Peritoneal Dialysis. Journal of the American Society of Nephrology: JASN, 2016, 27, 3238-3252.	6.1	366
83	Racial and Ethnic Disparities in Use of and Outcomes with Home Dialysis in the United States. Journal of the American Society of Nephrology: JASN, 2016, 27, 2123-2134.	6.1	77
84	Incremental Hemodialysis, Residual Kidney Function, and Mortality Risk in Incident Dialysis Patients: A Cohort Study. American Journal of Kidney Diseases, 2016, 68, 256-265.	1.9	186
85	The Evolving Ethics of Dialysis in the United States. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 704-709.	4.5	26
86	Pre-dialysis serum sodium and mortality in a national incident hemodialysis cohort. Nephrology Dialysis Transplantation, 2016, 31, 992-1001.	0.7	41
87	Association of Vascular Access Type with Mortality, Hospitalization, and Transfer to In-Center Hemodialysis in Patients Undergoing Home Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 298-307.	4.5	31
88	Association of Body Mass Index with Mortality in Peritoneal Dialysis Patients: A Systematic Review and Meta-Analysis. Peritoneal Dialysis International, 2016, 36, 315-325.	2.3	43
89	Effect of Medicare Dialysis Payment Reform on Use of Erythropoiesis Stimulating Agents. Health Services Research, 2015, 50, 790-808.	2.0	18
90	Association of Thyroid Functional Disease With Mortality in a National Cohort of Incident Hemodialysis Patients. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1386-1395.	3.6	57

#	Article	IF	Citations
91	Patient and Technique Survival of Older Adults with Esrd Treated with Peritoneal Dialysis. Peritoneal Dialysis International, 2015, 35, 612-617.	2.3	21
92	Hypomagnesemia and Mortality in Incident HemodialysisÂPatients. American Journal of Kidney Diseases, 2015, 66, 1047-1055.	1.9	63
93	Maintenance Dialysis throughout the World in Years 1990 and 2010. Journal of the American Society of Nephrology: JASN, 2015, 26, 2621-2633.	6.1	159
94	Predictors of treatment with dialysis modalities in observational studies for comparative effectiveness research. Nephrology Dialysis Transplantation, 2015, 30, 1208-1217.	0.7	48
95	The intact nephron hypothesis in reverse: an argument to support incremental dialysis. Nephrology Dialysis Transplantation, 2015, 30, 1602-1604.	0.7	32
96	Pharmacokinetic Assessment in Patients Receiving Continuous RRT. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 159-164.	4.5	48
97	Association of plasma F2-isoprostanes and isofurans concentrations with erythropoiesis-stimulating agent resistance in maintenance hemodialysis patients. BMC Nephrology, 2015, 16, 79.	1.8	9
98	KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 Update. American Journal of Kidney Diseases, 2015, 66, 884-930.	1.9	822
99	Peritoneal Equilibration Test and Patient Outcomes. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1990-2001.	4.5	59
100	Changes in symptom burden and physical performance with initiation of dialysis in patients with chronic kidney disease. Hemodialysis International, 2015, 19, 147-150.	0.9	12
101	ISPD Cardiovascular and Metabolic Guidelines in Adult Peritoneal Dialysis Patients Part I – Assessment and Management of Various Cardiovascular Risk Factors. Peritoneal Dialysis International, 2015, 35, 379-387.	2.3	123
102	ISPD Cardiovascular and Metabolic Guidelines in Adult Peritoneal Dialysis Patients Part II – Management of Various Cardiovascular Complications. Peritoneal Dialysis International, 2015, 35, 388-396.	2.3	55
103	Urine matrix metalloproteinase-7 and risk of kidney disease progression and mortality in type 2 diabetes. Journal of Diabetes and Its Complications, 2015, 29, 1024-1031.	2.3	22
104	A Pilot Randomized Crossover Trial Assessing the Safety and Short-Term Effects of Pomegranate Supplementation in Hemodialysis Patients., 2015, 25, 40-49.		24
105	An Estimation of the Prevalence and Progression of Chronic Kidney Disease in a Rural Diabetic Cambodian Population. PLoS ONE, 2014, 9, e86123.	2.5	16
106	Severe vascular calcification and tumoral calcinosis in a family with hyperphosphatemia: a fibroblast growth factor 23 mutation identified by exome sequencing. Nephrology Dialysis Transplantation, 2014, 29, 2235-2243.	0.7	19
107	Dialysis Therapies. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 812-814.	4.5	12
108	Comparative Mortality–Predictability Using Alkaline Phosphatase and Parathyroid Hormone in Patients on Peritoneal Dialysis and Hemodialysis. Peritoneal Dialysis International, 2014, 34, 732-748.	2.3	45

#	Article	IF	CITATIONS
109	Insulin resistance in chronic kidney disease: a step closer to effective evaluation and treatment. Kidney International, 2014, 86, 243-245.	5.2	26
110	The changing landscape of home dialysis in the United States. Current Opinion in Nephrology and Hypertension, 2014, 23, 586-591.	2.0	53
111	Health Insurance, Access to Care, and ESRD: An Intricate Web. Journal of the American Society of Nephrology: JASN, 2014, 25, 1135-1136.	6.1	1
112	Estimated GFR and Circulating 24,25-Dihydroxyvitamin D3ÂConcentration: A Participant-Level Analysis of 5 Cohort Studies and Clinical Trials. American Journal of Kidney Diseases, 2014, 64, 187-197.	1.9	62
113	Effect of Age and Dialysis Vintage on Obesity Paradox in Long-term Hemodialysis Patients. American Journal of Kidney Diseases, 2014, 63, 612-622.	1.9	81
114	Comparative Outcomes Between Continuous Ambulatory and Automated Peritoneal Dialysis: A Narrative Review. American Journal of Kidney Diseases, 2014, 63, 1027-1037.	1.9	68
115	Alkaline phosphatase: Better than <scp>PTH</scp> as a marker of cardiovascular and bone disease?. Hemodialysis International, 2014, 18, 720-724.	0.9	10
116	Diagnostic Testing for Peritonitis in Patients Undergoing Peritoneal Dialysis. Seminars in Dialysis, 2014, 27, 602-606.	1.3	9
117	The Kidney Research National Dialogue. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1806-1811.	4.5	18
118	Surviving the First Year of Peritoneal Dialysis: Enduring HardÂTimes. American Journal of Kidney Diseases, 2014, 64, 673-676.	1.9	3
119	A Palliative Approach to Dialysis Care. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 2203-2209.	4.5	120
120	Is Early Initiation of Dialysis Harmful?. Seminars in Dialysis, 2014, 27, 250-252.	1.3	13
121	Initiation of Dialysis Should be Timely: Neither Early Nor Late. Seminars in Dialysis, 2013, 26, 644-649.	1.3	24
122	Peritoneal Dialysis–Associated Peritonitis with Simultaneous Exit-Site Infection. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 126-130.	4.5	15
123	Nutritional Issues in Peritoneal Dialysis Patients: How Do They Differ From That of Patients Undergoing Hemodialysis?., 2013, 23, 237-240.		13
124	Comparing Mortality of Peritoneal and Hemodialysis Patients in the First 2 Years of Dialysis Therapy. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 619-628.	4.5	133
125	Using Hemoglobin A1c to Derive Mean Blood Glucose in Peritoneal Dialysis Patients. American Journal of Nephrology, 2013, 37, 413-420.	3.1	20
126	Serum creatinine level, a surrogate of muscle mass, predicts mortality in peritoneal dialysis patients. Nephrology Dialysis Transplantation, 2013, 28, 2146-2155.	0.7	75

#	Article	IF	CITATIONS
127	No independent association of serum phosphorus with risk for death or progression to end-stage renal disease in a large screen for chronic kidney disease. Kidney International, 2013, 84, 989-997.	5.2	54
128	Could longer and more frequent haemodialysis improve outcomes?. Nature Reviews Nephrology, 2013, 9, 74-75.	9.6	9
129	Is Female Sex Really a Risk Factor for Infectious Death in Peritoneal Dialysis?. Peritoneal Dialysis International, 2013, 33, 475-478.	2.3	5
130	Adverse effects of systemic glucose absorption with peritoneal dialysis. Current Opinion in Nephrology and Hypertension, 2013, 22, 663-668.	2.0	22
131	American Society of Nephrology Quiz and Questionnaire 2012: Renal Replacement Therapy. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1632-1636.	4.5	0
132	Dialysis Modality and Correction of Uremic Metabolic Acidosis: Relationship with All-Cause and Cause-Specific Mortality. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 254-264.	4.5	78
133	Estimated GFR Reporting Influences Recommendations for Dialysis Initiation. Journal of the American Society of Nephrology: JASN, 2013, 24, 1737-1742.	6.1	6
134	Should Glucose-Sparing Prescriptions Be Expected to Reduce the Cardiovascular Risk of Peritoneal Dialysis Patients?. Journal of the American Society of Nephrology: JASN, 2013, 24, 1713-1716.	6.1	4
135	Translating an Understanding of the Determinants of Technique Failure to Maximize Patient Time on Peritoneal Dialysis?. Peritoneal Dialysis International, 2013, 33, 112-115.	2.3	3
136	Is Dorothy Correct? The Role of Patient Education in Promoting Home Dialysis. Seminars in Dialysis, 2013, 26, 138-142.	1.3	10
137	Medication Reconciliation and Therapy Management in Dialysis-Dependent Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1988-1999.	4.5	67
138	Neighborhood Location, Rurality, Geography, and Outcomes of Peritoneal Dialysis Patients in the United States. Peritoneal Dialysis International, 2012, 32, 322-331.	2.3	49
139	Mortality Associated with Dose Response of Erythropoiesis-Stimulating Agents in Hemodialysis versus Peritoneal Dialysis Patients. American Journal of Nephrology, 2012, 35, 198-208.	3.1	36
140	Comparing Mandated Health Care Reforms. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1535-1543.	4.5	31
141	Reimbursement of Dialysis. Journal of the American Society of Nephrology: JASN, 2012, 23, 1291-1298.	6.1	121
142	Dialysis Modality and Outcomes in Kidney Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 332-341.	4.5	52
143	How to Overcome Barriers and Establish a Successful Home HD Program. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 2023-2032.	4.5	61
144	Searching for new care models for chronic kidney disease. Kidney International, 2012, 82, 621-623.	5.2	4

#	Article	IF	CITATIONS
145	Serum Potassium and Cause-Specific Mortality in a Large Peritoneal Dialysis Cohort. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1272-1284.	4.5	118
146	Relationship of body size and initial dialysis modality on subsequent transplantation, mortality and weight gain of ESRD patients. Nephrology Dialysis Transplantation, 2012, 27, 3631-3638.	0.7	33
147	Considerations in the optimal preparation of patients for dialysis. Nature Reviews Nephrology, 2012, 8, 381-389.	9.6	67
148	Associations Between Access to Care and Awareness of CKD. American Journal of Kidney Diseases, 2012, 59, S16-S23.	1.9	29
149	Expanding Access to Peritoneal Dialysis for Incident Dialysis Patients. American Journal of Kidney Diseases, 2012, 59, 330-332.	1.9	4
150	Insights into nephrologist training, clinical practice, and dialysis choice. Hemodialysis International, 2012, 16, 242-251.	0.9	31
151	Change in ankle-brachial index over time and mortality in diabetics with proteinuria. Clinical Nephrology, 2012, 78, 335-345.	0.7	5
152	Diets and enteral supplements for improving outcomes in chronic kidney disease. Nature Reviews Nephrology, 2011, 7, 369-384.	9.6	147
153	An Update on the Comparisons of Mortality Outcomes of Hemodialysis and Peritoneal Dialysis Patients. Seminars in Nephrology, 2011, 31, 152-158.	1.6	49
154	Vitamin D Supplementation in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 50-62.	4.5	264
155	Vitamin D and Cardiovascular Disease: Potential Role in Health Disparities. Journal of Health Care for the Poor and Underserved, 2011, 22, 23-38.	0.8	28
156	Implications of a Nephrology Workforce Shortage for Dialysis Patient Care. Seminars in Dialysis, 2011, 24, 275-277.	1.3	18
157	Novel Equations to Estimate Lean Body Mass in Maintenance Hemodialysis Patients. American Journal of Kidney Diseases, 2011, 57, 130-139.	1.9	67
158	84 Comparing Mortality Risk of Minerals, PTH and Alkaline Phosphatase Over 6 Years in 12,422 Chronic Peritoneal Dialysis (CPD) Patients. American Journal of Kidney Diseases, 2011, 57, B37.	1.9	0
159	Serum Albumin as a Predictor of Mortality in Peritoneal Dialysis: Comparisons With Hemodialysis. American Journal of Kidney Diseases, 2011, 58, 418-428.	1.9	199
160	Racial and Ethnic Differences in the Association of Body Mass Index and Survival in Maintenance Hemodialysis Patients. American Journal of Kidney Diseases, 2011, 58, 574-582.	1.9	72
161	Bridging the Care Gap Around Dialysis Initiation: Is CKD Education Part of the Solution?. American Journal of Kidney Diseases, 2011, 58, 160-161.	1.9	11
162	Similar Outcomes With Hemodialysis and Peritoneal Dialysis in Patients With End-Stage Renal Disease. Archives of Internal Medicine, 2011, 171, 110-8.	3.8	398

#	Article	IF	Citations
163	Association of Hemoglobin and Survival in Peritoneal Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1973-1981.	4.5	30
164	Glycemic Control and Survival in Peritoneal Dialysis Patients with Diabetes Mellitus. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1041-1048.	4.5	123
165	Association of Pretransplant Serum Phosphorus with Posttransplant Outcomes. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2712-2721.	4.5	19
166	Choice of dialysis modality. Kidney International, 2011, 80, 909-911.	5.2	13
167	Assessment of Glycemic Control in Dialysis Patients with Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1520-1522.	4.5	40
168	Peritoneal dialysis: an underutilized modality. Current Opinion in Nephrology and Hypertension, 2010, 19, 573-577.	2.0	34
169	Association of Hemodialysis Treatment Time and Dose With Mortality and the Role of Race and Sex. American Journal of Kidney Diseases, 2010, 55, 100-112.	1.9	106
170	Impact of race on hyperparathyroidism, mineral disarrays, administered vitamin D mimetic, and survival in hemodialysis patients. Journal of Bone and Mineral Research, 2010, 25, 2724-2734.	2.8	82
171	Measuring Vascular Calcification Clinical Practice. Seminars in Dialysis, 2010, 23, 263-266.	1.3	2
172	What Should Define Optimal Correction of Metabolic Acidosis in Chronic Kidney Disease?. Seminars in Dialysis, 2010, 23, 411-414.	1.3	9
173	ASN End-Stage Renal Disease Task Force. Journal of the American Society of Nephrology: JASN, 2010, 21, 1235-1237.	6.1	20
174	Lessons from Haiti on Disaster Relief. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 2122-2129.	4.5	15
175	Prevalence and Prognostic Significance of Renal Artery Calcification in Patients with Diabetes and Proteinuria. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 2093-2100.	4.5	24
176	Association of Cumulatively Low or High Serum Calcium Levels with Mortality in Long-Term Hemodialysis Patients. American Journal of Nephrology, 2010, 32, 403-413.	3.1	80
177	The Obesity Paradox and Mortality Associated With Surrogates of Body Size and Muscle Mass in Patients Receiving Hemodialysis. Mayo Clinic Proceedings, 2010, 85, 991-1001.	3.0	268
178	Understanding Sources of Dietary Phosphorus in the Treatment of Patients with Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 519-530.	4.5	395
179	Coronary artery calcification and mortality in diabetic patients with proteinuria. Kidney International, 2010, 77, 1107-1114.	5.2	78
180	Organic and inorganic dietary phosphorus and its management in chronic kidney disease. Iranian Journal of Kidney Diseases, 2010, 4, 89-100.	0.1	82

#	Article	IF	Citations
181	The outcomes of continuous ambulatory and automated peritoneal dialysis are similar. Kidney International, 2009, 76, 97-107.	5.2	104
182	Vitamin D and the Cardiovascular System. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1515-1522.	4.5	159
183	Effect of high-normal compared with low-normal arterial pH on protein balances in automated peritoneal dialysis patients. American Journal of Clinical Nutrition, 2009, 90, 1532-1540.	4.7	25
184	Pill Burden, Adherence, Hyperphosphatemia, and Quality of Life in Maintenance Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1089-1096.	4.5	470
185	Ownership Patterns of Dialysis Units and Peritoneal Dialysis in the United States: Utilization and Outcomes. American Journal of Kidney Diseases, 2009, 54, 289-298.	1.9	55
186	Correction of Metabolic Acidosis to Ameliorate Wasting in Chronic Kidney Disease: Goals and Strategies. Seminars in Nephrology, 2009, 29, 67-74.	1.6	35
187	Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney International, 2009, 76, 977-983.	5.2	184
188	Poor correlation between coronary artery calcification and obstructive coronary artery disease in an end-stage renal disease patient. Hemodialysis International, 2008, 12, 16-22.	0.9	29
189	60: Mortality Trend of Hemodialysis Chains in the USA: 1996-2004. American Journal of Kidney Diseases, 2008, 51, B42.	1.9	0
190	96: Comparing Mortality of Chronic Peritoneal and Maintenance Hemodialysis Patients in the 21st Century Up to 5 Years. American Journal of Kidney Diseases, 2008, 51, B51.	1.9	0
191	Racial Differences in Mortality and ESRD. American Journal of Kidney Diseases, 2008, 52, 205-208.	1.9	19
192	Cardiovascular Implications of Chronic Kidney Disease in Older Adults. Drugs and Aging, 2008, 25, 241-253.	2.7	14
193	Battleground. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 168-173.	4.5	38
194	Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease?. American Journal of Clinical Nutrition, 2008, 88, 1511-1518.	4.7	291
195	Serum Alkaline Phosphatase Predicts Mortality among Maintenance Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2008, 19, 2193-2203.	6.1	217
196	Racial Differences in Mortality Among Those with CKD. Journal of the American Society of Nephrology: JASN, 2008, 19, 1403-1410.	6.1	127
197	Nodular glomerulosclerosis in a patient with metabolic syndrome without diabetes. Nature Clinical Practice Nephrology, 2008, 4, 639-642.	2.0	17
198	Hypovitaminosis D in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 1144-1151.	4.5	141

#	Article	lF	Citations
199	Higher Strength Lanthanum Carbonate Provides Serum Phosphorus Control With a Low Tablet Burden and Is Preferred by Patients and Physicians: A Multicenter Study. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 1437-1445.	4.5	39
200	Looking for adequate return on investment: timing of educating patients about dialysis modalities. Peritoneal Dialysis International, 2008, 28, 347-8.	2.3	0
201	Is the Declining Use of Long-Term Peritoneal Dialysis Justified by Outcome Data?. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 1317-1328.	4.5	67
202	Chronic Peritoneal Dialysis in the United States. Journal of the American Society of Nephrology: JASN, 2007, 18, 2781-2788.	6.1	136
203	Serum and Dialysate Potassium Concentrations and Survival in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 999-1007.	4.5	288
204	VASCULAR CALCIFICATION IN PATIENTS WITH KIDNEY DISEASE: Vascular Calcification and Disordered Mineral Metabolism in Dialysis Patients. Seminars in Dialysis, 2007, 20, 139-143.	1.3	48
205	144. American Journal of Kidney Diseases, 2007, 49, B60.	1.9	0
206	The John F. Maher Award Recipient Lecture 2006. The continuum of chronic kidney disease and end-stage renal disease: challenges and opportunities for chronic peritoneal dialysis in the United States. Peritoneal Dialysis International, 2007, 27, 125-30.	2.3	1
207	Dietary protein requirements and dialysate protein losses in chronic peritoneal dialysis patients. Peritoneal Dialysis International, 2007, 27, 192-5.	2.3	31
208	Changing patterns of peritoneal dialysis utilization in the United States. Peritoneal Dialysis International, 2007, 27 Suppl 2, S51-2.	2.3	4
209	Disordered Mineral Metabolism and Vascular Calcification in Nondialyzed Chronic Kidney Disease Patients., 2006, 16, 100-118.		37
210	Strong association of carotid plaques with mortality and cardiovascular morbidity in hemodialysis patients. Nature Clinical Practice Nephrology, 2006, 2, 620-621.	2.0	0
211	Peritoneal dialysis penetration in the United States: march toward the fringes?. Peritoneal Dialysis International, 2006, 26, 419-22.	2.3	13
212	Serum fetuin-A in nondialyzed patients with diabetic nephropathy: Relationship with coronary artery calcification. Kidney International, 2005, 67, 1070-1077.	5 . 2	132
213	Patient education and access of ESRD patients to renal replacement therapies beyond in-center hemodialysis. Kidney International, 2005, 68, 378-390.	5.2	269
214	Progression of coronary artery calcification in diabetics with and without chronic kidney disease. Kidney International, 2005, 68, 1258-1266.	5.2	63
215	Coronary artery calcification in nondialyzed patients with chronic kidney diseases. American Journal of Kidney Diseases, 2005, 45, 963.	1.9	9
216	Diabetes and progression of coronary calcium under the influence of statin therapy. American Heart Journal, 2005, 149, 695-700.	2.7	77

#	Article	IF	Citations
217	Education, research, peritoneal dialysis, and the North American chapter of the International Society for Peritoneal Dialysis. Peritoneal Dialysis International, 2005, 25, 14-5.	2.3	11
218	Determinants of coronary artery calcification in diabetics with and without nephropathy. Kidney International, 2004, 66, 2022-2031.	5.2	93
219	POOR NUTRITIONAL STATUS AND INFLAMMATION: Metabolic Acidosis and Malnutritionâ€Inflammation Complex Syndrome in Chronic Renal Failure. Seminars in Dialysis, 2004, 17, 455-465.	1.3	160
220	Differential management of cardiovascular disease in ESRD by nephrologists and cardiologists. American Journal of Kidney Diseases, 2004, 44, 309-321.	1.9	6
221	Age-related decline in serum parathyroid hormone in maintenance hemodialysis patients is independent of inflammation and dietary nutrient intake., 2004, 14, 134-142.		12
222	Coronary artery, aortic wall, and valvular calcification in nondialyzed individuals with type 2 diabetes and renal disease. Kidney International, 2003, 64, 263-271.	5.2	109
223	Protein and energy nutrition among adult patients treated with chronic peritoneal dialysis. Advances in Chronic Kidney Disease, 2003, 10, 194-212.	2.1	36
224	Reducing peritonitis rates in a peritoneal dialysis program of indigent ethnic minorities. Peritoneal Dialysis International, 2003, 23, 83-5.	2.3	4
225	Emphasizing patient choice: the modality selection project in ESRD Network 18. Nephrology News & Issues, 2003, 17, 30-6.	0.1	1
226	Improvement of nutritional status after initiation of maintenance hemodialysis. American Journal of Kidney Diseases, 2002, 40, 133-142.	1.9	79
227	An analysis of dialysis training in the United States and Canada. American Journal of Kidney Diseases, 2002, 40, 152-160.	1.9	118
228	NUTRITIONALMANAGEMENT OFMAINTENANCEDIALYSISPATIENTS: Why Aren't We Doing Better?. Annual Review of Nutrition, 2001, 21, 343-379.	10.1	140
229	Peritoneal Dialysis Should be the First Choice of Initial Renal Replacement Therapy for More Patients With End-Stage Renal Disease. ASAIO Journal, 2001, 47, 309-311.	1.6	4
230	Treatment of advanced renal failure: Low-protein diets or timely initiation of dialysis?. Kidney International, 2000, 58, 1381-1388.	5.2	40
231	Another Call for Timely Initiation of Dialysis. Blood Purification, 2000, 18, 313-316.	1.8	1
232	Low Protein Diets Are Not Needed in Chronic Renal Failure. Mineral and Electrolyte Metabolism, 1999, 25, 311-316.	1.1	14
233	Longitudinal Evaluation of a Renal Kt/VUrea of 2.0 as a Threshold for Initiation of Dialysis. ASAIO Journal, 1998, 44, M677-M681.	1.6	4
234	Hypokalemic metabolic alkalosis with hypomagnesuric hypermagnesemia and severe hypocalciuria: A new syndrome?. American Journal of Kidney Diseases, 1997, 29, 106-114.	1.9	17

#	Article	IF	CITATIONS
235	International Icodextrin Use and association with peritoneal membrane function, fluid removal, patient and technique survival. Kidney360, 0, , 10.34067/KID.0006922021.	2.1	4